BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31614009)

  • 1. TLE1 expression fails to distinguish between synovial sarcoma, atypical fibroxanthoma, and dermatofibrosarcoma protuberans.
    Pukhalskaya T; Smoller BR
    J Cutan Pathol; 2020 Feb; 47(2):135-138. PubMed ID: 31614009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics.
    Foo WC; Cruise MW; Wick MR; Hornick JL
    Am J Clin Pathol; 2011 Jun; 135(6):839-44. PubMed ID: 21571956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Utility of NKX2.2 and TLE1 Immunohistochemistry in the Differentiation of Ewing Sarcoma and Synovial Sarcoma.
    Rooper LM; Sharma R; Gocke CD; Belchis DA
    Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):174-179. PubMed ID: 28800015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of TLE1 in Malignant Melanoma With Spindle Cell Morphology: A Potential Diagnostic Pitfall.
    Morrell TJ; Xiong Y; Deng A; Dresser K; O'Donnell P; Cornejo KM
    Int J Surg Pathol; 2019 May; 27(3):259-262. PubMed ID: 30301396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases.
    Knösel T; Heretsch S; Altendorf-Hofmann A; Richter P; Katenkamp K; Katenkamp D; Berndt A; Petersen I
    Eur J Cancer; 2010 Apr; 46(6):1170-6. PubMed ID: 20189377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm.
    Kovarik CL; Hsu MY; Cockerell CJ
    J Cutan Pathol; 2004 Aug; 31(7):492-6. PubMed ID: 15239679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue microarray based immunohistochemical study of TLE1 in synovial sarcoma and its histologic mimics.
    Sivakoti S; Uppin SG; Uppin MS; Tara RP; Prayaga AK; Challa S
    Indian J Pathol Microbiol; 2021; 64(2):310-315. PubMed ID: 33851625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 protein immunoreactivity in fibrohistiocytic tumors of the skin.
    Lee CS; Chou ST
    Pathology; 1998 Aug; 30(3):272-5. PubMed ID: 9770192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial sarcoma.
    Valente AL; Tull J; Zhang S
    Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):408-13. PubMed ID: 23197007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms.
    Kosemehmetoglu K; Vrana JA; Folpe AL
    Mod Pathol; 2009 Jul; 22(7):872-8. PubMed ID: 19363472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of proton-sensing G-protein-coupled receptors in selected skin tumors.
    Nassios A; Wallner S; Haferkamp S; Klingelhöffer C; Brochhausen C; Schreml S
    Exp Dermatol; 2019 Jan; 28(1):66-71. PubMed ID: 30339292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression levels and the differential expression of transforming growth factor-beta receptors in dermatofibroma and dermatofibrosarcoma protuberans.
    Kubo M; Ihn H; Yamane K; Tamaki K
    Br J Dermatol; 2006 May; 154(5):919-25. PubMed ID: 16634896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of Transducer-like Enhancer of Split 1 Immunohistochemical Expression in Synovial Sarcoma: An Institution-based Cross-sectional Study.
    Qureshi MB; Uddin N; Tariq MU; Raheem A; Pervez S
    Cureus; 2019 Dec; 11(12):e6357. PubMed ID: 31938642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
    Haycox CL; Odland PB; Olbricht SM; Piepkorn M
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical validation of TLE1, a novel marker, for synovial sarcomas.
    Rekhi B; Basak R; Desai SB; Jambhekar NA
    Indian J Med Res; 2012 Nov; 136(5):766-75. PubMed ID: 23287123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases.
    Mentzel T; Schärer L; Kazakov DV; Michal M
    Am J Dermatopathol; 2007 Oct; 29(5):443-8. PubMed ID: 17890911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Utility of TLE1 (Transducer-Like Enhancer of Split 1) in Distinguishing Synovial Sarcoma from Mimicking Tumors.
    Qureshi MB; Tariq MU; Abdul-Ghafar J; Chundriger Q; Ud Din N
    Int J Gen Med; 2021; 14():9173-9179. PubMed ID: 34880656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: a study of 1,150 tumors and fetal and adult normal tissues.
    Fanburg-Smith JC; Miettinen M
    Hum Pathol; 2001 Sep; 32(9):976-83. PubMed ID: 11567228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is TLE1 Expression Limited to Synovial Sarcoma? Our Experience at Shifa International Hospital, Pakistan.
    Ali Z; Haroon Khan A; Rehman U; Faisal M; Ahmad IN; Mamoon N; Nasir H; Hameed Z
    Cureus; 2019 Nov; 11(11):e6259. PubMed ID: 31893185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatofibrosarcoma protuberans: a tumor in the wide spectrum of the bland-looking spindle cell lesions of the breast.
    Vecchio GM; Broggi G; Mulè A; Piombino E; Magro G
    Pathologica; 2019 Sep; 111(3):87-91. PubMed ID: 31748754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.